文献速递白血病

克隆优势是接受强化化疗的急性髓系白血病的不良预后因素

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy.
PubMed 文献 · Leukemia · 2020-06-24

该研究探讨肿瘤内异质性与急性髓系白血病(AML)预后的关系,发现基于批量测序估算的Shannon指数与单集落基因分型的克隆多样性相关(ρ=0.76)。在292例43基因测序的发现队列中,驱动突变数较高(HR=1.18,P=0.028)和Shannon指数较低(HR=0.68,P=0.048,反映克隆优势)独立于欧洲白血病网2017风险与更差总生存相关,并在1184例111基因测序的验证队列中得到验证(驱动突变数HR=1.16,P=1×10⁻⁵;Shannon指数HR=0.81,P=0.007)。

要点

  • Shannon指数可从批量测序估算,与单集落基因分型克隆多样性相关(ρ=0.76)。
  • 发现队列中驱动突变数较高(HR=1.18)和Shannon指数较低(HR=0.68)与更差总生存独立相关。
  • 验证队列中驱动突变数HR=1.16(P=1×10⁻⁵),Shannon指数HR=0.81(P=0.007)。

核心结论

  • 诊断时克隆优势与白血病表型相关,该表型允许新克隆快速扩增并驱动化疗后复发。

研究设计与样本

  • 发现队列为292例接受43基因测序的患者,验证队列为1184例接受111基因测序的患者。
  • 另对50例细胞遗传学正常的AML配对诊断/复发外显子进行再分析。

主要发现

  • Shannon指数可从批量测序估算,与单集落基因分型的克隆多样性相关(ρ=0.76)。
  • 发现队列中驱动突变数较高(HR=1.18,P=0.028)和Shannon指数较低(HR=0.68,P=0.048)独立于欧洲白血病网2017风险与更差总生存相关。
  • 验证队列中驱动突变数较高(HR=1.16,P=1×10⁻⁵)和Shannon指数较低(HR=0.81,P=0.007)与更差总生存相关。
  • 50例细胞遗传学正常AML中,诊断时克隆优势与复发时获得显著更多突变相关(P=6×10⁻⁶),即克隆清扫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intra-tumor heterogeneity portends poor outcome in many cancers. In AML, a higher number of drivers worsens prognosis. The Shannon Index is a robust metric of clonal heterogeneity that accounts for the number of clones, but also their relative abundance. We show that a Shannon Index can be estimated from bulk sequencing, which is correlated (ρ = 0.76) with clonal diversity from single-colony genotyping. In a discovery cohort of 292 patients with sequencing of 43 genes, a higher number of drivers (HR = 1.18, P = 0.028) and a lower Shannon Index (HR = 0.68, P = 0.048), the latter reflecting clonal dominance, are independently associated with worse OS independently of European LeukemiaNet 2017 risk. These findings are validated in an independent cohort of 1184 patients with 111-gene sequencing (number of drivers HR = 1.16, P = 1 × 10-5, Shannon Index HR = 0.81, P = 0.007). By re-interrogating paired diagnosis/relapse exomes from 50 cytogenetically normal AMLs, we find clonal dominance at diagnosis to be correlated with the gain of a significantly higher number of mutations at relapse (P = 6 × 10-6), hence with clonal sweeping. Our results suggest that clonal dominance at diagnosis is associated with the presence of a leukemic phenotype allowing rapid expansion of new clones and driving relapse after chemotherapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cerrano M, Duchmann M, Kim R, et al. Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. Leukemia. 2020. PMID: 32581253. doi:10.1038/s41375-020-0932-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。